According to a market report by Lucintel, the future of the global pulmonary arterial hypertension treatment market looks promising with opportunities in the hospital pharmacy, retail pharmacy, and online pharmacy markets. The global pulmonary arterial hypertension treatment market is expected to reach an estimated $10.3 billion by 2030 from $7.6 billion in 2024,at a CAGR of 5.2% from 2024 to 2030. The major drivers for this market are increased disease awareness, new medicine approvals, and breakthroughs in treatment options and greater awareness among healthcare professionals and patients regarding PAH has resulted in earlier identification and treatment.

A more than 150-page report to understand trends, opportunity and forecast in pulmonary arterial hypertension treatment market to 2030 by drug type (vasodilators, phosphodiesterase 5 inhibitors, endothelin receptor antagonists, and soluble guanylatecyclase stimulator), distribution channel (hospital pharmacies, retail pharmacies, online pharmacies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)

Lucintel forecasts that, within the drug type category, endothelin receptor antagonist will remain the largest segment over the forecast period due to the efficacy of Endothelin Receptor Antagonist in treating PAH.

Within the distribution channel category, hospital pharmacy will remain the largest segment due to they often carry a broad variety of drugs, including specific PAH treatments such as endothelin receptor antagonists, prostacyclin analogs, and phosphodiesterase-5 inhibitors.

Download sample by clicking on pulmonary arterial hypertension treatment market

In terms of regions, North America will remain the largest region over the forecast period.

United Therapeutics, Bayer, Actelion, copyright, Gilead Sciences, GlaxoSmithKline, Teva Pharmaceuticals, Eli Lilly and Company, Steady Med, Johnson & Johnson are the major suppliers in the pulmonary arterial hypertension treatment market.

This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or write us at [email protected]To get access of more than 1000 reports at fraction of cost visit Lucintel'sAnalytics Dashboard.

About Lucintel

At Lucintel, we offer solutions for you growth through game changer ideas and robust market &unmet needs analysis. We are based in Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20 years. We are quoted in several publications like the Wall Street Journal, ZACKS, and the Financial Times.

Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: [email protected]
Tel. +1-972-636-5056

Explore Our Latest Publications

Smart Electric Drive Market

Thyristor Discrete Semiconductor Market

Thyristor Surge Protection Devices (TSPD) Market

Thyroid Cancer Diagnostic Market

UV Disinfection Equipment Market